Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 10/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13854076 | 0.77 | — | — | |
| SCHEMBL24133924 | 0.75 | FUCA1 (0.38) | FUCA1MTNR1AGLAMTNR1BNPSR1 | |
| SCHEMBL16316029 | 0.72 | — | — | |
| SCHEMBL9058544 | 0.71 | — | — | |
| SCHEMBL2863034 | 0.70 | — | — | |
| SCHEMBL17249606 | 0.70 | — | — | |
| SCHEMBL4663635 | 0.70 | — | — | |
| SCHEMBL1866565 | 0.70 | FUCA1 (0.40) | FUCA1MTNR1AGLAMTNR1BNPSR1 | |
| SCHEMBL1865707 | 0.69 | FUCA1 (0.41) | FUCA1MTNR1AGLAMTNR1BNPSR1 | |
| SCHEMBL15461404 | 0.69 | FUCA1 (0.41) | FUCA1MTNR1AGLAMTNR1BNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785424-B2 | ngCycloartanone derivatives with anticancer activity | PIERRE FABRE MEDICAMENT (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785424-B2 | ngCycloartanone derivatives with anticancer activity | PIERRE FABRE MEDICAMENT (FR) | 2014-07-22 | — | — | US | disclosed |
| US-20120077777-A1 | NGCYCLOARTANONE DERIVATIVES WITH ANTICANCER ACTIVITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-03-29 | — | — | US | disclosed |
| US-20120077777-A1 | NGCYCLOARTANONE DERIVATIVES WITH ANTICANCER ACTIVITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-03-29 | — | — | US | disclosed |
| WO-2010133687-A1 | CYCLOARTANONE DERIVATIVES WITH ANTICANCER ACTIVITY | PIERRE FABRE MEDICAMENT (FR) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077777-A1 | NGCYCLOARTANONE DERIVATIVES WITH ANTICANCER ACTIVITY | PKD1, NME1, NGLY1 | FUCA1 1286/4885MTNR1A 4036/4885GLA 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.